Reply to: " To target or not to target viral antigens in HBV related HCC?
by Buschow et al. First, Buschow et al challenged our idea that HBV antigen can be used as a target for HCC immunotherapy, suggesting that in our HBV-TCR T cell treated patient we "lack evidence to conclude that T cells really acted on tumor cells".
They are instead proposing that the drop of HBsAg observed in the patient could be explained by the T cells targeting "some level of undetectable HBV infection of the transplanted liver" and not the HCC metastases.
In the liver-transplanted patient with extrahepatic HCC metastases described in our report (see supplementary material of our paper for the detailed clinical history) [1] , liver biopsies were obtained from the transplanted liver and from the extrahepatic HCC metastases. HBsAg was found only in HCC metastases and not in the liver.
Furthermore, despite not being on anti viral therapy, the patient sera was
HBsAg+ but consistently HBV-DNA negative (a test performed monthly for the first 3 years after transplantation and every 3 monthly thereafter). HBV-DNA was also not found in the biopsy of the transplanted liver, while a truncated HBV-DNA coding only for HBsAg was detected in the biopsy material of the HCC metastasis. We sequenced this integrated section of HBV-DNA and demonstrated that it was coding for a non-mutated sequence of the HBs183-91 region that is recognized by our HBs183-91-directed TCR.
We further characterized the extrahepatic HCC metastasis by staining them Last, Buschow et al argued that our therapy is characterized by high and unacceptable risk for the patient. Patient safety is our primary concern and this is why we treated our patient only after repetitive testing showing that HBV was undetectable in the transplanted liver. We agree that such therapy could carry risk to non-liver transplanted HCC patients, where HBV-specific TCR can also target non-malignant HBV infected hepatocytes. Nevertheless, immunotherapeutic approaches to boost T cell responses in patients with ongoing HBV replication in the liver are being actively considered by a number of groups; discussion of this is beyond the scope of this response.
However, we are developing a strategy involving mRNA TCR electroporation to shorten the length of TCR-expression on T cells with the goal of reducing the risk of liver damage in HCC patients who have not received a liver transplant [5] . A further alternative would be to include a suicide gene mechanism to allow transduced T cells to be eliminated in case of unwanted effects in vivo.
Here, we would like to focus the discussion on the setting of HCC relapses taken with caution and we agree that immunotherapy carries inherent risks [9] .
However the targeting of normal HBV infected hepatocytes in liver transplanted patients can be theoretically eliminated after a careful characterization of the patients' pathology, HLA-profile and the subsequent precise and selective engineering of HBV-TCR T cells.
In conclusion, despite the criticisms expressed by Buschow et al., we are convinced that HBV antigen can be a target of HCC immunotherapy. Our data [1] , combined with the characterization of the frequency of HBV-RNA [8] and HBV-DNA integration in early [10] and late-onset [3, 6] HCC, support this possibility. Certainly we are far from concluding that HBV-TCR T cells constitute " the cure" for such devastating diseases, but we derived a "glimpse of hope" from our first attempt to target HBV antigen in HCC using engineered T cells.
Ironically, after having argued about the un-suitability of HBV as an HCC target, Buschow proposes to target " HBV mutated protein" in HCC, an option that is in agreement with our conclusion to evaluate HBV antigen as a target for HCC. However, it is not clear how HBV mutated sequences could be selectively expressed in HCC and not in normal HBV infected hepatocytes and why, differently from non mutated sequences, these should be stably expressed. Nevertheless, we welcome any discussions that boost research in this area and help design new therapies that can provide hope to the patients affected by HCC.
